MD783Z - Method for treating chronic atrophic gastritis - Google Patents
Method for treating chronic atrophic gastritis Download PDFInfo
- Publication number
- MD783Z MD783Z MDS20130164A MDS20130164A MD783Z MD 783 Z MD783 Z MD 783Z MD S20130164 A MDS20130164 A MD S20130164A MD S20130164 A MDS20130164 A MD S20130164A MD 783 Z MD783 Z MD 783Z
- Authority
- MD
- Moldova
- Prior art keywords
- treatment
- day
- atrophic gastritis
- orally
- chronic atrophic
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 208000016644 chronic atrophic gastritis Diseases 0.000 title claims abstract description 6
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 235000012054 meals Nutrition 0.000 claims abstract description 13
- 239000002113 nanodiamond Substances 0.000 claims abstract description 11
- 238000001802 infusion Methods 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 244000082872 Alchemilla vulgaris Species 0.000 claims abstract description 7
- 235000000008 Alchemilla vulgaris Nutrition 0.000 claims abstract description 7
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 241001072961 Pogostemon Species 0.000 claims abstract description 5
- 239000001738 pogostemon cablin oil Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 abstract description 3
- 208000006994 Precancerous Conditions Diseases 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010015137 Eructation Diseases 0.000 description 2
- 235000014066 European mistletoe Nutrition 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 240000002505 Pogostemon cablin Species 0.000 description 2
- 235000011751 Pogostemon cablin Nutrition 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 240000007313 Tilia cordata Species 0.000 description 2
- 241000221012 Viscum Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 150000004008 N-nitroso compounds Chemical class 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 241000983746 Saccharina latissima Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Invenţia se referă la medicină, în special la gastrologie şi poate fi utilizată pentru tratamentul gastritei cronice atrofice. The invention relates to medicine, in particular to gastrology and can be used for the treatment of chronic atrophic gastritis.
Se cunoaşte că depistarea şi tratamentul stărilor precanceroase ale stomacului reprezintă profilaxia secundară a cancerului gastric (Беспалов В. Г. Индивидуальная профилактика рака. Питер, 2001, p. 123-126). It is known that the detection and treatment of precancerous conditions of the stomach represents the secondary prophylaxis of gastric cancer (Bespalov V. G. Individual cancer prevention. Peter, 2001, p. 123-126).
În present, la principalele stări precanceroase ale stomacului se referă gastrita cronică atrofică şi infectarea cu Helicobacter pilori, iar la schimbările precanceroase principale se referă metaplazia intestinală şi displazia intestinală a epiteliului gastric (Аруин Л. И. Капуллер Л. Л. Исаков В. А. Морфологическая диагностика желудка и кишечника. Москва, Триада-Х, 1998, p. 269-300). Currently, the main precancerous conditions of the stomach include chronic atrophic gastritis and Helicobacter pylori infection, and the main precancerous changes include intestinal metaplasia and intestinal dysplasia of the gastric epithelium (Aruin L. I. Kapuller L. L. Isakov V. A. Morphological diagnosis of the stomach and intestines. Moscow, Triada-X, 1998, p. 269-300).
Unul dintre factorii principali ai apariţiei cancerului gastric îl joacă compuşii ce conţin nitraţi (Bartsch H., Frank N. Blocking the endogenous formation N-nitroso compounds and related carcenogens//In. Principles of Chemoprevention Ed. By. B. W. Stevart, D. Mc. Gregor, P. Kleihues - IARC Sci. Publ. Nr. 139, Lyon, France: International Agency for Research on Cancer, 1996, p. 189-201). One of the main factors in the occurrence of gastric cancer is played by compounds containing nitrates (Bartsch H., Frank N. Blocking the endogenous formation N-nitroso compounds and related carcinogens//In. Principles of Chemoprevention Ed. By. B. W. Stevart, D. Mc. Gregor, P. Kleihues - IARC Sci. Publ. No. 139, Lyon, France: International Agency for Research on Cancer, 1996, p. 189-201).
Este cunoscută metoda de tratament al stărilor precanceroase gastrice, care constă în aceea că se administrează un remediu medicamentos ce conţine decoct din flori de tei şi din partea aeriană de vâsc alb, amestec din mediul de cultură RPMI 1640 şi celule stem, extract proteic din ţesut tumoral, în următorul raport al componentelor, în % mas.: decoct din flori de tei 10, decoct din partea aeriană de vâsc alb 20, amestec din mediul de cultură RPMI 1640 şi celule stem 35, extract proteic din ţesut tumoral 35. Administrarea se efectuează per os de 4…5 ori pe zi, cu 30 min înainte de masă, câte 20 mL timp de 60…120 zile [1]. The method of treating gastric precancerous conditions is known, which consists in administering a medicinal remedy containing a decoction of linden flowers and the aerial part of white mistletoe, a mixture of RPMI 1640 culture medium and stem cells, and a protein extract from tumor tissue, in the following ratio of components, in % by weight: decoction of linden flowers 10, decoction of the aerial part of white mistletoe 20, a mixture of RPMI 1640 culture medium and stem cells 35, and protein extract from tumor tissue 35. The administration is carried out orally 4…5 times a day, 30 min before meals, 20 mL each for 60…120 days [1].
Dezavantajul acestei metode constă în aceea că este complicată în vederea obţinerii remediului medicamentos şi poate provoca reacţii alergice la pacienţii cu astm bronşic. The disadvantage of this method is that it is complicated to obtain the medicinal remedy and can cause allergic reactions in patients with bronchial asthma.
Mai este cunoscută metoda de tratament al stărilor precanceroase gastrice, care constă în aceea că se administrează remediul KLAMIN (concentrat din Laminaria saccharina L. Lamour), ce se obţine din fracţia lipidică a algelor brune de mare, câte 2 pastile de trei ori pe zi, cu 15…30 min înainte de masă, timp de 6 luni, cu repetarea curei de tratament peste 1…3 luni [2]. Another known method of treating gastric precancerous conditions is the administration of the remedy KLAMIN (concentrate from Laminaria saccharina L. Lamour), which is obtained from the lipid fraction of brown seaweed, 2 pills three times a day, 15…30 min before meals, for 6 months, with the treatment course repeated after 1…3 months [2].
Dezavantajul acestei metode constă în aceea că remediul KLAMIN conţine iod, din care cauză este contraindicat persoanelor care suferă de tireotoxicoză, insuficienţă renală şi hepatică cronică. The disadvantage of this method is that the KLAMIN remedy contains iodine, which is why it is contraindicated for people suffering from thyrotoxicosis, chronic renal and hepatic failure.
Se mai cunoaşte o metodă de tratament al stărilor precanceroase gastrice, care constă în aceea că se administrează per os o compoziţie ce conţine vitamina E şi β-caroten [3]. Another known method of treating gastric precancerous conditions consists in administering a composition containing vitamin E and β-carotene orally [3].
Dezavantajul acestei metode constă în aceea că compoziţia se administrează timp îndelungat, devenind posibilă cumularea vitaminei liposolubile în organism, ceea ce duce la manifestarea unui şir de efecte adverse. The disadvantage of this method is that the composition is administered for a long time, making it possible for the fat-soluble vitamin to accumulate in the body, which leads to the manifestation of a number of adverse effects.
În calitate de cea mai apropiată soluţie se cunoaşte metoda de tratament al gastritei cronice atrofice, care constă în aceea că se administrează infuzie din Alchemilla vulgaris L., ce conţine acid silicic coloidal hidratat în cantitate de 0,12 g/100 mL, calculat pentru siliciu, câte 200 mL, per os, de 4 ori pe zi, cu 20…30 min înainte de masă, timp de 4 luni [4]. As the closest solution, the method of treatment of chronic atrophic gastritis is known, which consists in administering an infusion of Alchemilla vulgaris L., containing hydrated colloidal silicic acid in an amount of 0.12 g/100 mL, calculated for silicon, 200 mL each, orally, 4 times a day, 20…30 min before meals, for 4 months [4].
Dezavantajul acestei metode constă în aceea că tratamentul este de lungă durată şi poate provoca reacţii adverse ca greaţă şi vomă după utilizare. The disadvantage of this method is that the treatment is long-lasting and can cause side effects such as nausea and vomiting after use.
În ultimul deceniu au apărut mai multe cercetări în domeniul nanodiamantelor, pentru prima dată nanodiamantele au fost sintetizate în 1963 şi au fost aplicate în tehnologii şi industrie. Diamantele naturale sunt cunoscute ca pietre scumpe. Ele fiind dure, rezistente, posedă o capacitate înaltă de conductibilitate termică. După al II-lea război mondial a fost posibil tehnologic de sintetizat diamantele, în aşa fel a apărut industria de fabricare a diamantelor sintetice. Semnificativ este faptul că în procesul activităţii sale degajă căldură şi că ele pot pătrunde în membrana celulară şi pot precipita pe suprafaţa sferică mai multe celule de substanţe biologic active, medicamente, polimere etc. Aceste caracteristici au stat la baza aplicării nanodiamantelor cu scop de dezintoxicare. În aşa fel în anul 2000 nanodiamantele au fost folosite la pacienţii oncologici care au fost supuşi radio- şi chimioterapiei, cu scop de dezintoxicare. In the last decade, several researches in the field of nanodiamonds have appeared, for the first time nanodiamonds were synthesized in 1963 and were applied in technologies and industry. Natural diamonds are known as precious stones. Being hard, resistant, they possess a high thermal conductivity capacity. After World War II, it was technologically possible to synthesize diamonds, thus the synthetic diamond manufacturing industry appeared. Significant is the fact that in the process of its activity it releases heat and that they can penetrate the cell membrane and precipitate on the spherical surface several cells of biologically active substances, drugs, polymers, etc. These characteristics were the basis for the application of nanodiamonds for the purpose of detoxification. Thus, in 2000, nanodiamonds were used in oncological patients who were subjected to radio- and chemotherapy, for the purpose of detoxification.
Problema pe care o soluţionează invenţia constă în lărgirea gamei de metode utilizate în tratamentul stărilor precanceroase gastrice care la administrare nu ar provoca reacţii adverse ca vomă şi greaţă, ar fi mai uşor şi ieftin de preparat şi ar avea un efect terapeutic mai eficient. The problem that the invention solves consists in expanding the range of methods used in the treatment of gastric precancerous conditions which, upon administration, would not cause adverse reactions such as vomiting and nausea, would be easier and cheaper to prepare and would have a more effective therapeutic effect.
Conform invenţiei, metoda revendicată constă în aceea că se administrează 200 mL de un amestec ozonat pe bază de ulei de Pogostemon patchouli, ce conţine nanodiamante de 4…10 nm, în concentraţie de 10-9…10-10 g/L cu concentraţia ozonului de 8000…10000 µg/L, per os, de două ori pe zi, cu o oră înainte de masă, şi concomitent 200 mL de o infuzie de Alchemilla vulgaris L., per os, o dată pe zi, cu 20 min înainte de masă, seria de tratament constituie 2 luni. According to the invention, the claimed method consists in administering 200 mL of an ozonated mixture based on Pogostemon patchouli oil, containing nanodiamonds of 4…10 nm, in a concentration of 10-9…10-10 g/L with an ozone concentration of 8000…10000 µg/L, orally, twice a day, one hour before a meal, and simultaneously 200 mL of an infusion of Alchemilla vulgaris L., orally, once a day, 20 min before a meal, the treatment series is 2 months.
Soluţia ozonată se obţine în felul următor: într-un vas de 15 L se toarnă 10 L Oleum Pogostemon cablin, apoi se adaugă praf de nanodiamante în concentraţie de 10-9…10-10 g/L de ulei, după care soluţia se malaxează până la omogenizare, apoi soluţia se ozonează până la 8000…10000 µg/L de ozon. Praful de nanodiamante de 4…10 nm este obţinut conform brevetului RU 2465376 C1 2012.10.27 şi este accesibil pentru procurare în Federaţia Rusă. Oleum Pogostemon cablin este accesibil spre procurare în reţeaua de farmacii din ţară şi de peste hotare. Infuzia de Alchemilla vulgaris L. se obţine în felul următor: se pregăteşte materia primă din partea vegetală (partea aeriană), apoi materia primă se plasează într-un vas şi se toarnă apă la o temperatură de 100°C, apa şi materia vegetală se iau în raport de 10:1. Infuzia se lasă la temperatura camerei timp de 24 ore, după care ea poate fi utilizată în tratamentul stărilor precanceroase. The ozonated solution is obtained as follows: in a 15 L vessel, 10 L of Oleum Pogostemon cablin is poured, then nanodiamond powder is added in a concentration of 10-9…10-10 g/L of oil, after which the solution is kneaded until homogenous, then the solution is ozonized to 8000…10000 µg/L of ozone. The 4…10 nm nanodiamond powder is obtained according to patent RU 2465376 C1 2012.10.27 and is available for purchase in the Russian Federation. Oleum Pogostemon cablin is available for purchase in the pharmacy network in the country and abroad. The infusion of Alchemilla vulgaris L. is obtained in the following way: the raw material from the plant part (aerial part) is prepared, then the raw material is placed in a vessel and water at a temperature of 100°C is poured over it, water and plant material are taken in a ratio of 10:1. The infusion is left at room temperature for 24 hours, after which it can be used in the treatment of precancerous conditions.
Rezultatul tehnic constă în aceea că metoda de tratament revendicată nu provocă reacţii adverse ca vomă şi greaţă şi posedă un efect terapeutic mai ridicat. The technical result is that the claimed treatment method does not cause adverse reactions such as vomiting and nausea and has a higher therapeutic effect.
Avantajul invenţiei revendicate constă în obţinerea rezultatului terapeutic în decurs de 2 luni, cu două luni mai repede faţă de soluţia cea mai apropiată, nu provoacă reacţii adverse ca vomă şi greaţă, soluţia administrată nu necesită utilaj sofisticat la preparare şi este comodă în administrare, în ceea ce priveşte eficienţa tratamentului - după 24 de zile se observă o evidenţiere a pliurilor mucoasei gastrice şi dispariţia eructaţiei, pe când în soluţia cea mai apropiată evidenţierea pliurilor se observa la 80…94 de zile după începerea tratamentului. The advantage of the claimed invention consists in obtaining the therapeutic result within 2 months, two months faster than the closest solution, it does not cause adverse reactions such as vomiting and nausea, the administered solution does not require sophisticated equipment for preparation and is convenient to administer, in terms of treatment efficiency - after 24 days, a highlighting of the folds of the gastric mucosa and the disappearance of eructation are observed, while in the closest solution, the highlighting of the folds is observed 80...94 days after the start of treatment.
Metoda revendicată se efectuează în felul următor: se pregătesc soluţia şi infuzia, se administrează 200 mL de un amestec ozonat pe bază de ulei de Pogostemon patchouli, ce conţine nanodiamante de 4…10 nm, în concentraţie de 10-9…10-10 g/L cu concentraţia ozonului de 8000…10000 µg/L, per os, de două ori pe zi, cu o oră înainte de masă, şi concomitent 200 mL de o infuzie de Alchemilla vulgaris L., per os, o dată pe zi, cu 20 min înainte de masă, seria de tratament constituie 2 luni. The claimed method is performed as follows: the solution and infusion are prepared, 200 mL of an ozonated mixture based on Pogostemon patchouli oil, containing nanodiamonds of 4…10 nm, in a concentration of 10-9…10-10 g/L with an ozone concentration of 8000…10000 µg/L, orally, twice a day, one hour before a meal, and simultaneously 200 mL of an infusion of Alchemilla vulgaris L., orally, once a day, 20 min before a meal, the treatment series is 2 months.
Exemplu de realizare Example of implementation
Pacienta A., 46 ani, acuza eructaţie cu miros fetid, greutate în regiunea epigastrică, meteorism, dureri gastrice ce se intensifică după alimentaţie. FEGPS (Fibroesofagogastroscopia) - mucoasa gastrică atrofică, pliurile mucoase sunt denivelate. Pacienta a primit tratament conform metodei revendicate, s-au administrat 200 mL de un amestec ozonat pe bază de ulei de Pogostemon patchouli, ce conţine nanodiamante de 4…10 nm, în concentraţie de 10-9…10-10 g/L cu concentraţia ozonului de 8000…10000 µg/L, per os, de două ori pe zi, cu o oră înainte de masă, şi concomitent 200 mL de o infuzie de Alchemilla vulgaris L., per os, o dată pe zi, cu 20 min înainte de masă, timp de 2 luni. După aceasta, la investigaţiile efectuate ulterior s-a stabilit dispariţia semnelor clinice şi ameliorarea stării pacientei. Pacienta nu a avut efecte adverse la tratamentul efectuat conform metodei revendicate. Patient A., 46 years old, complains of belching with a fetid odor, heaviness in the epigastric region, flatulence, gastric pain that intensifies after eating. FEGPS (Fibroesophagogastroscopy) - atrophic gastric mucosa, mucosal folds are uneven. The patient received treatment according to the claimed method, 200 mL of an ozonated mixture based on Pogostemon patchouli oil, containing nanodiamonds of 4…10 nm, in a concentration of 10-9…10-10 g/L with an ozone concentration of 8000…10000 µg/L, orally, twice a day, one hour before meals, and simultaneously 200 mL of an infusion of Alchemilla vulgaris L., orally, once a day, 20 min before meals, for 2 months. After this, subsequent investigations established the disappearance of clinical signs and improvement of the patient's condition. The patient had no adverse effects from the treatment performed according to the claimed method.
Toţi pacienţii care au fost trataţi conform metodei revendicate, în număr de 41, au fost monitorizaţi pe parcursul unui an, reacţii adverse şi recidive nu s-au depistat. All patients who were treated according to the claimed method, 41 in number, were monitored for one year, no adverse reactions or relapses were detected.
1. MD 3972 C2 2010.08.31 1. MD 3972 C2 2010.08.31
2. RU 2034560 C1 1995.05.10 2. RU 2034560 C1 1995.05.10
3. WO 9102535 A1 1991.03.31 3. WO 9102535 A1 1991.03.31
4. MD 611 Z 2013.03.31 4. MD 611 Z 2013.03.31
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20130164A MD783Z (en) | 2013-10-08 | 2013-10-08 | Method for treating chronic atrophic gastritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20130164A MD783Z (en) | 2013-10-08 | 2013-10-08 | Method for treating chronic atrophic gastritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD783Y MD783Y (en) | 2014-06-30 |
| MD783Z true MD783Z (en) | 2015-01-31 |
Family
ID=51022559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20130164A MD783Z (en) | 2013-10-08 | 2013-10-08 | Method for treating chronic atrophic gastritis |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD783Z (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991002535A1 (en) * | 1989-08-11 | 1991-03-07 | Basil, Inc. | Cancer prevention composition and method |
| RU2034560C1 (en) * | 1993-05-18 | 1995-05-10 | Товарищество с ограниченной ответственностью "Фитолон" | Cancer prevention "clamin" remedy |
| MD3773G2 (en) * | 2008-05-30 | 2009-09-30 | Ион МЕРЕУЦЭ | Agent for treating precancerous mucous membrane and tegument affections |
| MD3972C2 (en) * | 2009-03-11 | 2010-07-31 | Ион МЕРЕУЦЭ | Remedy and method for treating precancerous conditions |
| MD611Z (en) * | 2012-02-14 | 2013-10-31 | Раиса МЕРЕУЦА | Method for treatment of chronic atrophic gastritis |
-
2013
- 2013-10-08 MD MDS20130164A patent/MD783Z/en not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991002535A1 (en) * | 1989-08-11 | 1991-03-07 | Basil, Inc. | Cancer prevention composition and method |
| RU2034560C1 (en) * | 1993-05-18 | 1995-05-10 | Товарищество с ограниченной ответственностью "Фитолон" | Cancer prevention "clamin" remedy |
| MD3773G2 (en) * | 2008-05-30 | 2009-09-30 | Ион МЕРЕУЦЭ | Agent for treating precancerous mucous membrane and tegument affections |
| MD3972C2 (en) * | 2009-03-11 | 2010-07-31 | Ион МЕРЕУЦЭ | Remedy and method for treating precancerous conditions |
| MD611Z (en) * | 2012-02-14 | 2013-10-31 | Раиса МЕРЕУЦА | Method for treatment of chronic atrophic gastritis |
Also Published As
| Publication number | Publication date |
|---|---|
| MD783Y (en) | 2014-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016370126B2 (en) | Medicine composition for treating leukemia and preparation method therefor | |
| CN102697893A (en) | Application of black raspberry extract (BRBE) in preparation of drugs for treating gastric cancer | |
| EP3701970A2 (en) | Immunity-boosting agent, immuno-therapeutic anti-cancer agent, and anti-cancer therapy adverse effect mitigating agent containing anthocyanin-fucoidan complex as active ingredient | |
| RU2533446C2 (en) | Method for increasing physical endurance of body exposed to ultraviolet irradiation | |
| EA027651B1 (en) | Biologically active food additive for normalizing the function of the thyroid gland | |
| Bose et al. | In vitro evaluation of anti-proliferative activity of protein from Litchi chinensis honey against human cervical cancer cell line (HeLa) | |
| CN104623215B (en) | A kind of antitumor medicine composition | |
| MD783Z (en) | Method for treating chronic atrophic gastritis | |
| CN102114065B (en) | Composition of Desmodium and Tripterygium wilfordii traditional Chinese medicine with anti-cancer effect and application thereof | |
| RU2443427C1 (en) | Anthelminthic agent | |
| CN101732377A (en) | Method for preparing anti-cancer total saponin extracts of oplopanax elatus nakai leaves | |
| CN102232957B (en) | Use of 3-acetoxyl-8, 24-lanostadiene-21-acid in preparing medicines for preventing or treating liver cancer or breast cancer | |
| RU2836810C1 (en) | Herbal veterinary compositions against nematodes | |
| US20200000847A1 (en) | Pharmaceutical composition for treating leukemia and method for preparing the same | |
| CN103432247B (en) | Traditional Chinese medicine effective part composition for treating ischemic stroke and preparation method thereof | |
| JP7588388B2 (en) | IL-18 production inhibitor | |
| CN109010495A (en) | A kind of Chinese medicine composition and its preparation method and application | |
| BR102021024155A2 (en) | USE OF A SOLUTION/EMULSION FROM ZIZIPHUS COTINIFOLIA REISSEK IN THE TREATMENT OF ANXIETY DISORDERS | |
| TWI674894B (en) | Medicament for treating melanoma and uses of the same | |
| KR20040026274A (en) | The health-supporting food having the effect of anti-tumor and its preparation method | |
| BG4014U1 (en) | Syrup composition preventing the negative side effects of chemotherapy | |
| KR101359528B1 (en) | Radiation protective composition comprising effective bee-venom and royal jelly | |
| MD611Z (en) | Method for treatment of chronic atrophic gastritis | |
| Kovalev et al. | Grounding of semisolid medicinal forms production on nature components | |
| CN118236444A (en) | Traditional Chinese medicine composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |